Vita Therapeutics is a Baltimore, Maryland cell engineering company, spun out of Johns Hopkins University in 2019 and formally founded in 2020, that develops induced pluripotent stem cell (iPSC) derived cellular therapies for neuromuscular disease and solid tumors. Its programs pair an autologous approach with an allogeneic, universal hypoimmunogenic approach, and include VTA-100 and VTA-110 for limb-girdle muscular dystrophy and related muscular dystrophies such as FSHD. The company raised a $31M Series B led by Cambrian BioPharma and Solve FSHD and operates from the University of Maryland BioPark. It is a clinical-stage biotechnology company: it sells no software, runs no developer program, and publishes no public API, SDK, webhook or machine-readable contract of any kind.
Vita Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Cell Therapy, Life Sciences, and Health.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: vita-therapeutics
name: Vita Therapeutics
description: 'Vita Therapeutics is a Baltimore, Maryland cell engineering company, spun out of Johns Hopkins University in
2019 and formally founded in 2020, that develops induced pluripotent stem cell (iPSC) derived cellular therapies for neuromuscular
disease and solid tumors. Its programs pair an autologous approach with an allogeneic, universal hypoimmunogenic approach,
and include VTA-100 and VTA-110 for limb-girdle muscular dystrophy and related muscular dystrophies such as FSHD. The company
raised a $31M Series B led by Cambrian BioPharma and Solve FSHD and operates from the University of Maryland BioPark. It
is a clinical-stage biotechnology company: it sells no software, runs no developer program, and publishes no public API,
SDK, webhook or machine-readable contract of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/vita-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-04'
modified: '2026-09-04'
tags:
- Company
- Biotechnology
- Cell Therapy
- Life Sciences
- Health
- Pharmaceuticals
- Research
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/vita-therapeutics-domain-security.yml
- type: Website
url: https://www.vitatx.com/
- type: LinkedIn
url: https://www.linkedin.com/company/vita-therapeutics
x-enrichment:
date: '2026-09-04'
status: minimal
artifacts_added: 2
pass: local-v3
x-coverage:
state: none
reason: not-a-software-company
detail: 'Vita Therapeutics is a clinical-stage iPSC cell-therapy developer whose product is a biologic, not software: there
is no developer program, no GitHub organization, no package on any registry, and its own corporate site at www.vitatx.com
is currently unpublished and returns a Webflow 404 on every path, while the apex vitatx.com fails the TLS handshake outright.'
evidence:
- url: https://www.vitatx.com/
status: 404
- url: https://www.vitatx.com/.well-known/agent-card.json
status: 404
- url: https://www.vitatx.com/openapi.json
status: 404
- url: https://www.vitatx.com/llms.txt
status: 404
- url: https://vitatx.com/
status: 0
checked: '2026-09-04'
Kin Score
How this is scored →